Core Viewpoint - The article discusses the impact of temporary restrictions on certain industries, highlighting that these sectors often experience significant revenue and profit growth after initial market panic subsides. The underlying reason for this recovery is the competitive advantage of domestic companies, particularly due to the abundance of engineering graduates in China [2][4]. Group 1: Market Reactions and Recovery - When temporary restrictions are imposed, stock prices in affected sectors tend to fluctuate more than the overall market [2]. - After the market panic dissipates, industries that faced restrictions have shown substantial year-on-year growth in revenue and profits since 2023-2024 [2]. - Historically, industries that have been restricted by the U.S. have eventually seen a resurgence in their fundamentals [2]. Group 2: Competitive Advantages - The restrictions often arise because domestic companies possess competitive advantages, commonly referred to as the "engineer dividend" [2]. - China has the largest number of engineering graduates globally, providing a cost advantage in sectors requiring a large number of engineers [2][3]. - For instance, in the innovative pharmaceutical sector, an engineer in China earns about one-third of the salary of a comparable engineer in Europe or the U.S., enhancing competitive positioning [3]. Group 3: Future Outlook - The engineer dividend is expected to persist for a considerable time, with the number of high school graduates projected to peak around 2035, sustaining this advantage until approximately 2045 [4]. - While Western tech companies excel in initial innovation, Chinese firms are adept at scaling innovations efficiently, creating distinct competitive advantages in the global market [4]. Group 4: Investment Implications - Market reactions are often driven by investor sentiment in the short term, but over time, stock prices align with fundamental performance [5]. - The best investment opportunities arise during periods of market panic when stock prices are undervalued, leading to potential gains as fundamentals recover and stock prices rise [5].

Group 1 - Guangdong Province is focusing on talent recruitment and development as a key strategy for modernizing its industrial system, with a series of meetings held throughout the year to address this issue [1][2] - The province has set ambitious goals, such as the "Million Talents Gathering in South Guangdong" initiative, which aims to attract 1 million college graduates to work and start businesses in the region [1][7] - In 2024, Guangdong's GDP is projected to reach 14 trillion yuan, maintaining its position as the top economic province in China for 36 consecutive years, supported by a growing population and employment opportunities [3][4] Group 2 - The shift from a "demographic dividend" to an "engineer dividend" is underway, with a significant increase in skilled and high-skilled talent in Guangdong, which is essential for the province's industrial transformation [4][5] - As of mid-2024, Guangdong has 19.19 million skilled workers and 7.22 million high-skilled workers, reflecting a robust talent pool that supports the province's economic growth [4] - The province's modern vocational education system is the largest in the country, with a continuous increase in enrollment in vocational schools, contributing to a stable supply of skilled labor [5][6] Group 3 - The government is under pressure to attract high-quality, innovative talent that aligns with industrial development, emphasizing the need for a comprehensive talent evaluation system [6][7] - Challenges remain in quickly adjusting talent structures to meet industry needs, enhancing salary competitiveness, and providing long-term benefits to retain talent [8] - A collaborative discussion involving experts, government officials, and industry representatives is planned to explore new strategies for talent development in Guangdong [8]

Core Insights - China's economic development is supported by three significant advantages: stock population dividend, delayed gratification dividend, and engineer dividend [2][3][4] - The rise of Chinese manufacturing and technological innovation is an inevitable trend, with a focus on integrating technological and industrial innovation during the 14th Five-Year Plan [5][6] Group 1: Economic Advantages - The stock population dividend is characterized by a large base of 1.4 billion people, which supports substantial industries and business models [3][4] - The delayed gratification dividend reflects the high labor participation and savings rates in China, leading to a rapid capital formation speed [3][4] - The engineer dividend indicates China's fastest technological innovation speed globally [3][4] Group 2: Technological Innovation - China is emerging as a significant global research engine, maintaining the highest quality research output and leading in PCT international patent applications for six consecutive years [4][5] - The 14th Five-Year Plan is expected to emphasize the integration of technological and industrial innovation, with key industries such as artificial intelligence, marine economy, and biomedicine projected to grow significantly [5][6] Group 3: Capital Market Trends - The rapid rise of technological innovation in China is influencing the capital market, with A-share market capitalization surpassing 100 trillion yuan, a 15.6% increase from the end of 2024 [7][8] - The current capital market conditions resemble those of previous high-growth periods, driven by macroeconomic recovery and favorable liquidity conditions [7][8] - The central government aims to enhance the attractiveness and inclusivity of the domestic capital market, which is expected to support high-quality development in technology and industry [8][9]

9月11日，国新办举行"高质量完成'十四五'规划"系列主题新闻发布会，介绍"十四五"时期卫生健康工作 发展成就。据介绍，我国在研新药数量占全球数量的比例超过20%，跃居全球新药研发第二位。 过去几年，中国创新药获得突飞猛进的发展，国际影响力迅速提升。一项报告显示，2024年，中国创新 药对外授权金额超过500亿美元，占全球总交易额30%。今年上半年，全球医药交易数量达456笔，同比 增长32%；交易总金额高达1304亿美元，同比增长58%，其中，涉及中国的交易贡献了近50%的总金额 和超过30%的交易数量。摩根士丹利的一份报告预测到2040年，源自中国的创新药将占美国FDA（食品 药品监督管理局）新药批准的35%。 其次，美国药企更加依赖中国创新药而不是相反。美国大型药企核心产品专利逐渐到期，用较低的价格 购买中国创新药专利，能够填补其专利到期的缺口，保持完整的管线，确保未来业务保持可持续的增 长。如果美国药企无法继续购买中国企业授权，那么其在短期内即使投入很高的研发成本也并不一定能 够产生成果，反而可能面临较大的风险。 其三，中国企业正在贡献全球1/3的创新药物专利，而全球购买授权的大型跨国药企，有一半来自 ...

9月11日，国新办举行"高质量完成'十四五'规划"系列主题新闻发布会，介绍"十四五"时期卫生健康工作 发展成就。据介绍，我国在研新药数量占全球数量的比例超过20%，跃居全球新药研发第二位。 但实际上，近期辉瑞、默沙东等美国制药巨头与中国药企签下的创新药授权协议不断刷新规模，相当一 部分中美药企在创新药产业链上下游的深化合作已成趋势。首先，在中国创新药的对外授权交易中，美 国药企通过购买中国创新药授权，获取中国企业的知识产权与产品，而非中国企业并购美国企业并获得 其技术。 其次，美国药企更加依赖中国创新药而不是相反。美国大型药企核心产品专利逐渐到期，用较低的价格 购买中国创新药专利，能够填补其专利到期的缺口，保持完整的管线，确保未来业务保持可持续的增 长。如果美国药企无法继续购买中国企业授权，那么其在短期内即使投入很高的研发成本也并不一定能 够产生成果，反而可能面临较大的风险。 其三，中国企业正在贡献全球1/3的创新药物专利，而全球购买授权的大型跨国药企，有一半来自欧 洲，日本等其他地区药企也积极寻求与中国企业合作。因此，若美国限制中国创新药准入，长远来看可 能削弱其在全球制药行业的领先地位。 9月11日的创新 ...

文 | 银行螺丝钉 （转载请注明出处） 今天大盘低开高走，整体大幅上涨，截止到收盘，回到4.2星。 大中小盘股都上涨较多。 成长风格大幅上涨，创业板、科创板上涨较多。 创业板指上涨超过5%。 创业板之前涨幅落后于科创板，最近也逐渐崛起，目前还在正常估值。 倒不是说价值风格会下跌，而是上涨涨幅会少一些。 今天自由现金流、价值等指数也是上涨。 关于红利、自由现金流等指数的估值，螺丝钉也做了估值表，供参考，见文章下方图片。 港股略微下跌。 今天港股医药波动比较大。 港股创新药等指数，在2季度大幅上涨，在8月达到高估，后面几周出现回调。 昨晚特朗普对国内创新药企业推出一些限制，导致港股恒生创新药等指数下跌比较多。 不过港股医药，因为前段时间上涨较多，最近回调后，也还在正常偏高的估值。 A股医药医疗受影响比较小，A股医药医疗指数整体上涨。 1. 有朋友问，美对国内创新药企业提出限制，会不会对创新药产生长久影响呢？ 成长风格强势的时候，价值风格就相对低迷。 这种限制，在2018年之后并不少见。 例如之前中移动因为被限制，被迫从美股退市。 前几年的中概股，也受到过影响。 再后来的军工、芯片、创新药，很多领域都遇到过。 2. ...

Core Viewpoint - The investment strategy conference held by Hua'an Fund emphasizes the identification of investment opportunities in A-shares, Hong Kong stocks, and global markets, focusing on sectors such as technology, AI, pharmaceuticals, consumption, high-end manufacturing, and military industry [1][3]. Group 1: Macro Insights - The global risk appetite has improved since the announcement of "equal tariffs" on April 8, which has implications for U.S. inflation and the dollar's strength [3]. - Despite a slowdown in investment and consumption growth in China, companies with global competitiveness are enhancing export resilience [3]. - Current low levels of Chinese government bond yields support equity assets, with risk premiums at historical 56th percentile, indicating equity still holds value [3]. Group 2: Sector Focus - Investment opportunities are highlighted in sectors such as AI, robotics, innovative pharmaceuticals, new consumption, and non-ferrous metals [3][11]. - The technology sector is seen as a key area for investment, with a focus on high-end manufacturing, smart vehicles, and innovative medical solutions [6][17]. - The conference discusses the balance of risk and return in the pharmaceutical sector and the potential of consumer recovery in specific sub-sectors [4]. Group 3: Investment Team Structure - Hua'an Fund boasts a robust investment management team of over 200 members, structured into a "three-generation talent ladder" to enhance investment strategies [7]. - The active equity investment team is organized into five groups: growth, value, balanced, industry selection, and multi-asset, facilitating efficient research-to-investment strategy conversion [7][5]. - The team includes specialists in various sectors, showcasing a blend of experience and innovation, which enhances the overall investment strategy [5][6]. Group 4: Future Trends - The shift from demographic dividends to engineer dividends in China is expected to sustain growth in high-skilled labor, with implications for sectors like technology and manufacturing [10][11]. - The current market is characterized by a "structural bull" driven by industrial confidence and risk appetite recovery, with a focus on identifying new demand and growth opportunities [12][15]. - Investment strategies will prioritize sectors with global competitiveness, including AI, biotechnology, innovative pharmaceuticals, and new energy [15][19].

9月11日，创新药纯度100%的港股通创新药ETF（520880）场内一度暴跌近8%，盘中溢价高企，显示买 盘资金尤为强劲。昨日，资金逢跌加仓港股通创新药ETF（520880）9849万元。至此，520880已连续7 日吸金，金额合计近2.8亿元。 9月8日，港股通创新药ETF（520880）跟踪的恒生港股通创新药精选指数"提纯"修订生效，全面剔除药 明系等CXO个股，同时新纳入14只纯正创新药企业，正式成为一只不含CXO、纯度100%的创新药指 数。本次"提纯"修订生效后，将彻底避免CXO对标的指数走势的干扰，有望在后续创新药行情启动时展 现出更强进攻性。据恒生指数公司统计，剔除CXO后，恒生港股通创新药精选指数历史回溯表现显著 更优。 今年以来，港股通创新药ETF（520880）跟踪的恒生港股通创新药精选指数在同类指数中进攻力 MAX，截至"提纯"修订生效前（9月5日），其年内累计涨幅达119.75%，领涨一众创新药指数。 展望后市，方正证券表示，创新药长牛行情或远未结束，中国工程师红利带来的创新药资产尚未充分兑 现商业化价值。港股创新药板块估值较低，BD落地数量多且确定性高，未来大赛道如小核酸、口服 G ...

创新药板块或进入阶段性整理期，AH股同频震荡。9月10日，A股创新药龙头股领跌，百利天恒重挫 5.3%，重仓创新药的药ETF（562050）场内跌0.86%两连阴。 港股通创新药调整幅度更大，创新药纯度100%的港股通创新药ETF（520880）场内跌1.35%，成交4.92 亿元。场内全天宽幅溢价，溢价率一度飙至0.66%，显示买盘资金尤为强劲。 从资金动向来看，近期520880吸金迅猛，截至9月9日已连续6日获净申购，金额合计逾1.8亿元，多头信 号强烈；近60日维度，资金净流入率更是超过165%。东方证券提示，当前或依然是配置创新药的极佳 时间点。 | 时 多日 = | F9 盘前盘后 缩加 九秒 图线 工具 @ (2) >> | | | | | 港船通创新药ETFO | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.68 | 520880[福設通创新药ETF] 15:00 价 0.660 版跌 -0.009[ | | | 0.660 -0.009 -1.35% | | | 520880 | | | 0.680 | | 1 ...

Group 1 - The innovative drug sector has shown significant growth in 2023, with the Hong Kong Stock Connect Innovative Drug Index rising by 125.35% as of September 8, 2025 [1] - The Chinese innovative drug industry has evolved from a follower to a leader, supported by favorable capital market conditions and new listing channels for unprofitable biotech companies [1][2] - The number of innovative drugs approved by the National Medical Products Administration (NMPA) in the first half of 2025 reached 43, with 40 developed by Chinese companies, indicating substantial progress in the industry [2] Group 2 - The overseas licensing of Chinese innovative drugs has reached nearly $66 billion in the first half of 2025, showcasing the growing international presence of Chinese pharmaceutical companies [2] - The innovative drug sector is currently in a booming phase, with a significant number of projects in clinical trials, and is expected to continue to be a development opportunity for several years [3] - The innovative drug sector is experiencing a temporary adjustment due to previous rapid gains and competition for investment from the technology sector [2][3] Group 3 - The Hong Kong market has a slight lead in innovative drug financing and development speed compared to the A-share market, with over 70 companies listed under the 18A rule since its introduction in 2018 [4][5] - The CSI Hong Kong Stock Connect Innovative Drug Index includes 50 top companies in the innovative drug sector, providing investors with a simplified selection process [5] - The innovative drug sector is expected to rebound in September, presenting new investment opportunities [5]